Ab­b­Vie drops Cy­tomX part­ner­ship, leav­ing PhII pro­gram in the air

Ab­b­Vie is wind­ing down its col­lab­o­ra­tion with Cy­tomX sev­en years af­ter first em­bark­ing on a search for con­di­tion­al­ly ac­ti­vat­ed can­cer im­munother­a­py pro­grams.

Cy­tomX will be weigh­ing its op­tions for CX-2029, a CD71-di­rect­ed an­ti­body-drug con­ju­gate, af­ter Ab­b­Vie de­cid­ed not to ad­vance the drug in­to ad­di­tion­al stud­ies, the biotech dis­closed in its quar­ter­ly up­date. The Big Phar­ma part­ner al­so served no­tice to ter­mi­nate their li­cens­ing deal, which dates back to 2016, on the same day.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN